We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Immunomedics (IMMU) - moderated
An SI Board Since September 2006
Posts SubjectMarks Bans Symbol
59243 337 15 IMMU
Emcee:  idahoranch1 Type:  Moderated
Welcome to the troll-free, moderated message board, made up of primarily ex-IMMU shareholders.
- IMMU's status:
--It is now a fully owned subsidiary of Gilead.

For those who want to continue to follow Trodelvy’s progress and IMMU’s pipeline:

Clinical trials

Prostate cancer

Trodelvy combined with PARP for TNBC

Phase lll Ascent trial. Halted for compelling efficacy

Rollover Study for patients who are still responding after their trial has ended

Study of IMMU-132 in HR+/HER2- MBC (TROPICs-02)
Trodelvy in TNBC (NeoSTAR). Primary end point—% of complete responses in treatment naive patients.

A Study of Sacituzumab Govitecan in Metastatic Solid Tumors (TROPICS-03)
Phase II Open Label, Study of IMMU-132 in Metastatic Urothelial Cancer (Trophy U-01)

Trodelvy is on the path to becoming standard of care in breast cancer. You heard it here first.


This board is moderated, meaning the moderator (me) can stop people from posting here if they violate our norms. What are "our norms"? Well, be adult, play nice about sums it up. There are three responses I encourage for keeping the discussion civil and useful when you encounter a post that annoys you. In order of preference:

1> report a ToU violation to the SI admins via the link at the bottom of each post, they're good at dealing with problems.

2> send the person who posted a private message and work it out. Privately.

3> send me a private message. Wait a couple of days before doing so please, I'll usually see the message in that time frame and act (or not).

4> stay focused and leave politics out of it, even by inference. There are numerous forums you can spend as much time expounding on your favorite "why (insert favorite hot-button) is evil", we don't need to reiterate all that here.

5> do not engage in discussions about poster's motivations, etc. First of all, it's unprovable. Second I'd rather not wade through the inevitable pointless back-and-forth over something that'll never be settled anyway.

This board provides a forum for honest, civilized and friendly conversation. It is not a vehicle for spam or hidden agendas. New posters are not only welcome but are an important way to bring additional information and insights to the board. Over the years new posters have been welcomed into the group and have helped make the board successful. However, if you’re a new poster it is especially important to be sure that material assertions, be they pro or con, are thoughtful and supportable. While all posters must abide by the TOU, leeway can and will be granted to long-time posters who have made substantive contributions to the board and whose credibility has been established.
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
59243Any thoughts on the following class, monoclonal antibody CCR5 receptor antagonidorightbythem-5 hours ago
59242Awaiting NK merger, good news in Pancreatic Cancer. Nantkwest Inc (NASDAQ: NK) dorightbythem26 hours ago
59241Hey Lonnie. Glad to hear others respond as well. It was a sleepless weekend. Woudorightbythem-6 hours ago
59240Mr Fitzhugh sent me information on AUPH a few months ago, but I wasn’t too keen idahoranch131 PM
59239I find them kind of like Trip Advisor. If one has the time, read 100 posts, scresysiphus16 AM
59238dorightbythem-4 AM
59237Just want to know if yahoo and stocktwits are to crazy for even the most common dorightbythem-1 AM
59236That is a good question and I agree that 1/3 at 30 would be prudent. The Otsukdorightbythem1yesterday
59235So, what’s the exit point for AUPH? They don’t have anything else in the pipelinli3511-yesterday
59234Very unusual day but rewarding after close as AUPH stopped trading around 4pm ETdorightbythem2Saturday
59233I see that there was an event on May 29, 2020 where the stock price dropped 72% dorightbythem-last Thursday
59232I think that RPRX is just the gift that keeps giving. This deal is good for botfmrick2last Thursday
59231Any thoughts on Royal Pharm's move on latest royalty play - Minerva Neuroscidorightbythem-last Thursday
592301. not sure which urslor1last Wednesday
59229Here's a comment and the 1st reason Morgan Stanley is justifying their buy osummer_sky6last Wednesday
59228Hey Lonnie. I had mentioned SAVA a couple months ago as my only speculative singscorman12last Tuesday
59227Hey guys, Not sure if you've caught this one flying last Friday and then toMFG ENG3last Tuesday
59226Well it’s up 25% now. With only 35 million shares, and addressing a market that idahoranch11last Tuesday
59225Gilead is up 6% today, apparently on this news: Gilead is up 18% sinOlecranon-last Tuesday
59224Idaho, you've let the cat out of the bag. SAVA is up 12% this morning.Olecranon-last Tuesday
59223CEO seems a little sketchy to me, but the articles that head that direction, so idahoranch12last Monday
59222Just looking back in our archives, I see that @scorman was asking about SAVA bacOlecranon-last Monday
59221That was my big question, how credible and competent is management? I read it jidahoranch1-last Monday
59220It's nice to see an article that delves so deep into the science and other fOlecranon-last Monday
59219I’m not touting this company, but from this Seeking Alpha article. Symbol SAVA, idahoranch12last Monday
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):